Document is current
Any future updates will be listed below
-
Authors
Silfverberg, Thomas https://orcid.org/0000-0002-3829-285X
Zjukovskaja, Christina https://orcid.org/0000-0003-0934-4478
Noui, Yassine https://orcid.org/0000-0002-0513-7546
Carlson, Kristina
,
Nahimi, Adjmal
Erik, Ahlstrand
Honar, Cherif
Arta, Dreimane
Sigrun, Einarsdottir
Jan, Fagius
Hans, Hägglund
Ellen, Iacobaeus
Niclas, Lange
Stig, Lenhoff
Per, Ljungman
Jan, Lycke
Johan, Mellergård
Fredrik, Piehl
Anders, Svenningsson
Andreas, Tolf
Burman, Joachim https://orcid.org/0000-0002-7045-1806
- License Information
-
More Information
Article History
Received: 12 March 2024
Revised: 18 July 2024
Accepted: 9 August 2024
First Online: 26 August 2024
Competing interests
: EI has received speakers fee from Merck and honoraria from advisory boards for Sanofi-Aventis, Biogen and Merck. FP previously received research grants from Merck KGaA, Janssen and UCB outside this study. FP has received payment for expert testimony from Novartis. FP has participated in Data Monitoring Committee for clinical trials from Chugai, Lundbeck and Roche. JM has received lecture honorarium from Merck. NL has received honoraria from Sanofi. All other individual authors declare that there is no competing financial interests.
: The Swedish Ethical Review Authority approved the study with identification number EPN Dnr 2021-01530 on 14 April 2021. Written informed consent was obtained from all study subjects. This study has been performed in accordance with the Declaration of Helsinki.
